Bharati Biotech finishes oral cholera vaccine trials

• Hillchol, an oral cholera vaccine, has completed phase III clinical trials.

• The trial evaluated safety, immunogenicity, non-inferiority, and consistency of Hillchol’s single component compared to a comparator vaccine.

• The trial involved 1,800 individuals across 10 clinical sites in India.

• Hillchol showed a 4-fold increase in vibriocidal antibodies against Ogawa and Inaba serotypes, proving non-inferiority to licensed vaccines.

• The trials will lead to Hillchol’s distribution in the next few months.